Search clinical trials for: Cisplatin

Total 3752 results

Lee's Pharmaceutical Limited

Not yet recruiting

Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer
Coherus Biosciences, Inc.

Not yet recruiting

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer (TRANSPARENT)

Nasopharyngeal Cancer Recurrent
Bayer

Not yet recruiting

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer | HER2 Mutation

United States, Korea, Republic of, Belgium, China, Japan, Taiwan, Denmark, Germany, Israel, Italy, United Kingdom, Bulgaria, Portugal, Switzerland, Greece, Turkey, Sweden, France, Singapore, Mexico, Spain, Netherlands, Poland, Brazil, A... and more
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Carcinoma, Pancreatic Ductal
Shanghai Zhongshan Hospital

Not yet recruiting

Combining Chemoradiotherapy With Sintilimab in First-Line ICC

ICC

China
Zachary Zumsteg

Not yet recruiting

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

Carcinoma | Oropharyngeal Cancer

United States
Sichuan University

Not yet recruiting

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Advanced Solid Tumor

China
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca; Universitätsklinikum Köln, Germany; Universitätsklinikum Düsseldorf...

Not yet recruiting

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Extrahepatic Cholangiocarcinoma | Unresectable Perihilar or Ductal CCA

Germany
The Christie NHS Foundation Trust
University College London Hospitals; University College, London; Royal Free Hospital...

Not yet recruiting

Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma (EMPHATIC)

Cholangiocarcinoma
Fundación GECP

Not yet recruiting

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN)

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Resectable Lung Non-Small Cell Carcinoma

Spain
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Non-Small Cell Lung Cancer With HER2- Mutations

China
Peking University Third Hospital
Jilin Provincial Tumor Hospital; Affiliated Hospital of Hebei University; Hebei...

Not yet recruiting

Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.

Cervical Cancer
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8 | Resectable Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Ductal Adenocarcinoma

United States
Zhejiang Cancer Hospital

Recruiting

Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (Stars)

Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma

China
University of Cologne
AstraZeneca

Not yet recruiting

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (GUIDANCE)

Small Cell Lung Carcinoma
Sun Yat-sen University

Not yet recruiting

TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer

Penile Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Toripalimab for High-risk Locally Advanced Cervical Cancer

Cervical Cancers

China
AstraZeneca
Daiichi Sankyo

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15)

Metastatic Non-small Cell Lung Cancer
National Cancer Institute (NCI)

Not yet recruiting

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Carcinoma, Neuroendocrine | Tumor, Neuroendocrine | Tumors, Neuroendocrine | Neuroendocrine; Carcinoma | Small Cell; Receptors

United States
GlaxoSmithKline

Not yet recruiting

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

United Kingdom
Centre Leon Berard
Groupe Français de Pneumo-Cancérologie

Not yet recruiting

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum (FIRST-NEC)

Large Cell Neuroendocrine Carcinoma of the Lung

France
University of Texas Southwestern Medical Center
Astellas Pharma Inc

Not yet recruiting

Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer (STAR-EV)

Bladder Cancer
RenJi Hospital

Recruiting

Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer

Immunotherapy | Locally Advanced Cervical Carcinoma | Concurrent Chemoradiotherapy

China
Yang Jianjun, PhD

Not yet recruiting

Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Xiamen University

Recruiting

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) (SEGNO)

Oligometastatic Prostate Cancer | Locally Advanced Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
Beijing Chest Hospital, Capital Medical University

Not yet recruiting

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC (NeoSCLC-001)

Limited-stage Small-cell Lung Cancer
Francesco De Cobelli
A.O. Ospedale Papa Giovanni XXIII; Cardarelli Hospital; AOU Pisana, Pisa, Italy

Recruiting

Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy (PM-CARE)

Intrahepatic Cholangiocarcinoma

Italy
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Neuroendocrine Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
Amgen

Recruiting

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

United States
Sun Jing

Not yet recruiting

A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Locally Advanced Esophageal Squamous Cell Carcinoma
University of Michigan Rogel Cancer Center

Not yet recruiting

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer (NEPTUNE)

Urothelial Carcinoma

United States
The Affiliated Hospital of Qingdao University

Recruiting

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer (PILOT)

Non-small-cell Lung Cancer (NSCLC)

China
Zhejiang Cancer Hospital

Recruiting

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Gastric Cancer | Colorectal Cancer | Pancreatic Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma | Liver Cancer Stage IV

China
National Cancer Institute, Naples

Recruiting

Neo-adjuvant Chemo and Immunotherapy in The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma

Cholangiocarcinoma

Italy
Zhujiang Hospital

Recruiting

RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients

Bladder Cancer | Muscle-Invasive Bladder Carcinoma

China
Hansoh BioMedical R&D Company

Not yet recruiting

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

Advanced Solid Tumors
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Cervical Cancer
Hansoh BioMedical R&D Company

Not yet recruiting

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Advanced Solid Tumor
Fujian Cancer Hospital

Not yet recruiting

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Metastatic Nasopharyngeal Carcinoma | Intermittent Systematic Chemotherapy
Denise Fabian

Not yet recruiting

Hypofractionated Radiochemotherapy

Uterine Cervix Cancer

United States
Sun Yat-sen University

Not yet recruiting

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Ohio State University Comprehensive Cancer Center

Recruiting

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Oropharyngeal Squamous Cell Carcinoma | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

United States
GlaxoSmithKline

Recruiting

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Neoplasms

United States, Spain, Korea, Republic of
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Hyogo Medical University
Merck Sharp & Dohme LLC

Not yet recruiting

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma (PENINSULA)

Malignant Pleural Mesothelioma

Japan

3

Subscribe